umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent
Swedish Institute for Health Economics, Lund.
Swedish Institute for Health Economics, Lund; Department of Clinical Sciences, Lund University, Malmö.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Dermatology and Venerology. Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine.ORCID iD: 0000-0002-3858-8474
2015 (English)In: Dermatology, ISSN 1018-8665, E-ISSN 1421-9832, Vol. 230, no 4, 347-353 p.Article in journal (Refereed) Published
Abstract [en]

Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naive patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naive patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations:The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients.

Place, publisher, year, edition, pages
S. Karger, 2015. Vol. 230, no 4, 347-353 p.
Keyword [en]
Biologic agents,  Intermittent treatment,  Continuous treatment,  Psoriasis,  Register
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:umu:diva-104914DOI: 10.1159/000371881ISI: 000354004000011PubMedID: 25721571OAI: oai:DiVA.org:umu-104914DiVA: diva2:821730
Available from: 2015-06-15 Created: 2015-06-15 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Schmitt-Egenolf, Marcus

Search in DiVA

By author/editor
Schmitt-Egenolf, Marcus
By organisation
Dermatology and VenerologyMedicine
In the same journal
Dermatology
Dermatology and Venereal Diseases

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 71 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf